Combination therapy overcomes BET inhibitor resistance, shows study

Scientists at St. Jude Children’s Research Hospital developed a novel combination therapy approach for a leukemia subtype harboring rearrangements in the KMT2A gene. The approach overcomes the cancer’s drug resistance, without adding toxicity. The study was published today in Proceedings of the National Academy of Sciences.

Leave A Comment

Your email address will not be published. Required fields are marked *